The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Bronchiolitis Obliterans Syndrome Market Over The Period 2026–2030?
The bronchiolitis obliterans syndrome market has witnessed significant expansion in recent years. Its value is projected to escalate from $1.59 billion in 2025 to $1.73 billion in 2026, progressing at a compound annual growth rate (CAGR) of 9.1%. This historic growth can be attributed to several factors including an increase in organ transplantation, the prevalence of chronic graft rejection cases, advancements in hospital pulmonary care, the ongoing usage of immunosuppressants, and the challenges posed by limited early diagnostics.
The market for bronchiolitis obliterans syndrome is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $2.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. Factors contributing to this growth during the forecast period include the increasing number of transplant procedures, advancements in early detection technologies, the emergence of personalized immunotherapy, the establishment of specialized respiratory centers, and a focus on long-term patient management. Key trends expected during the forecast period encompass enhanced monitoring after transplantation, the proliferation of immunosuppressive therapies, a broader scope of early diagnostic testing, an emphasis on preserving long-term lung function, and a heightened need for specialized pulmonary care.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24488&type=smp
Which Economic Or Industry Drivers Are Impacting The Bronchiolitis Obliterans Syndrome Market?
An escalating volume of lung transplant procedures is anticipated to fuel the expansion of the bronchiolitis obliterans syndrome market in the coming years. This procedure involves surgically substituting a patient’s impaired or non-functional lung with a healthy donor lung, aiming to enhance respiratory function. The rise in lung transplantations can be attributed to breakthroughs in surgical methodologies, which have substantially boosted success rates and minimized adverse events, rendering the operation safer and more readily available for patients requiring it. For individuals with advanced bronchiolitis obliterans syndrome, lung transplantation offers an effective treatment by substituting compromised lungs with healthy donor organs, thereby enhancing respiration and pulmonary performance. As an illustration, the Organ Procurement and Transplantation Network, a US-based non-profit scientific and educational organization, reported in January 2025 that lung transplants experienced their most significant proportional increase, rising from 3,026 transplants in 2023 to 3,340 in 2024, representing a 10.4 percent growth. Consequently, the increasing frequency of lung transplant operations is a key driver for the expansion of the bronchiolitis obliterans syndrome market.
How Is The Bronchiolitis Obliterans Syndrome Market Divided Into Its Major Segments?
The bronchiolitis obliterans syndrome market covered in this report is segmented –
1) By Treatment Type: Medication, Oxygen Therapy, Lung Transplant
2) By Diagnosis: Pulmonary Function Tests, Imaging Tests, Lung Biopsy, Other Diagnosis
3) By Disease Type: Acute Bronchiolitis, Chronic Bronchiolitis Obliterans Syndrome
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Medication: Immunosuppressants, Corticosteroids, Antibiotics, Bronchodilators, Anti-Inflammatory Agents
2) By Oxygen Therapy: Continuous Oxygen Therapy, Intermittent Oxygen Therapy, Portable Oxygen Therapy, Hyperbaric Oxygen Therapy
3) By Lung Transplant: Single Lung Transplant, Double Lung Transplant, Living Donor Lung Transplant, Retransplantation
How Are Trends Transforming The Bronchiolitis Obliterans Syndrome Market Landscape?
Leading companies within the bronchiolitis obliterans syndrome market are concentrating on developing advanced solutions, such as at-home nebulized therapy, to improve medication adherence and slow disease progression through targeted, continuous treatment. At-home nebulized therapy involves utilizing a nebulizer to convert liquid medication into a breathable mist, enabling direct delivery to the lungs. This convenient, self-administered treatment allows for effective management of respiratory conditions from the comfort of home. For instance, in March 2023, Renovion, Inc., a US-based clinical-stage pharmaceutical company, launched ARINA-1, which received Food and Drug Administration (FDA) Fast Track Designation for aiming at preventing the progression of bronchiolitis obliterans syndrome (BOS) in patients with bilateral lung transplants. This regulatory milestone emphasizes ARINA-1’s potential to address a crucial unmet medical need in transplant medicine. The Fast Track status facilitates more frequent communication with the FDA and prioritizes ARINA-1 for accelerated development and review, reflecting Renovion’s commitment to advancing respiratory health through innovative, patient-focused therapeutics.
Who Are The Prominent Organizations Shaping The Bronchiolitis Obliterans Syndrome Market?
Major companies operating in the bronchiolitis obliterans syndrome market are Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AstraZeneca plc, Sanofi S.A., Johnson & Johnson (Janssen), AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals Incorporated, United Therapeutics Corporation, Insmed Incorporated, Viatris Inc., Zydus Lifesciences Ltd., Cadila Pharmaceuticals Ltd.
Read the full bronchiolitis obliterans syndrome market report here:
What Are The Top-Performing Regions Within The Bronchiolitis Obliterans Syndrome Market?
North America was the largest region in the bronchiolitis obliterans syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchiolitis obliterans syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Bronchiolitis Obliterans Syndrome Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24488&type=smp
Browse Through More Reports Similar to the Global Bronchiolitis Obliterans Syndrome Market 2026, By The Business Research Company
Bronchitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/bronchitis-treatment-global-market-report
Reversible Airway Diseases Treatment Market Report 2026
Tracheitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/tracheitis-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model